Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Investigators patent pfDHODH inhibitors

Oct. 25, 2016

Melinta Therapeutics submits NDA to FDA for Baxdela

Oct. 25, 2016

Janssen presents phase I results for ExPEC4v

Oct. 24, 2016

NeuroVive and Arbutus terminate NVP-018 agreement

Oct. 24, 2016

Gilead Sciences provides results from phase III studies of sofosbuvir/velpatasvir/voxilaprevir

Oct. 24, 2016

FDA approves Zinplava to reduce recurrence of C. difficile infection

Oct. 24, 2016

Enanta Pharmaceuticals divulges anti-hepatitis B virus agents

Oct. 21, 2016

Novel DNA vaccines against Zika virus infection enter phase I study

Oct. 21, 2016

Pivotal phase III study of letermovir meets primary endpoint

Oct. 20, 2016

ContraVir Pharmaceuticals begins enrollment of next dosing group in phase IIa trial of CMX-157

Oct. 19, 2016

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 24, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
University of Southern California reports new MAPT aggregation inhibitors
BioWorld Science
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...